Emil Kongshøj Larsen, Executive Vice President for International Operations at Novo Nordisk, talks to BT about India’s role ...

Novo Nordisk finds itself navigating significant operational and market headwinds. The company is intensely focused on maintaining its leadership in the obes ...

Novo Nordisk NVO announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) ...

Eli Lilly ( LLY 1.19%) and Novo Nordisk ( NVO 2.44%) are two of the leading companies in the fast-growing GLP-1 weight loss ...

EMA issues positive opinion on Novo Nordisk's higher-dose Wegovy, supported by strong weight-loss data and ongoing reviews in ...

Even so, in an interview with The Economist, Mr Doustdar sounded confident that Novo can recover. His prescription is to push a new generation of obesity treatments while making sweeping changes to ...

CHONGQING, CHINA - SEPTEMBER 10: In this photo illustration, the logo of Novo Nordisk is displayed on a smartphone screen on September 10, 2025 in Chongqing, China. The maker of Wegovy and Ozempic, ...

Intent on growing its leading position in obesity and weight management drugs, Novo Nordisk has made an unsolicited, approximately up-to-$9 billion bid for Metsera—more than a month after Pfizer ...

Novo Nordisk is rated a 'Strong Buy' due to its undervaluation, wide economic moat, and long-term growth prospects despite recent setbacks. Novo Nordisk's Q3/25 results showed slowing growth, lowered ...

Initiating coverage on Novo Nordisk with a Strong Buy, 70% below its all-time high. NVO's competitive pressures and US political pricing risks are midterm noise. Global obesity and diabetes markets ...

Sluggish growth for Novo Nordisk's GLP-1 drugs caused the company to again reduce its full-year sales guidance. Novo Nordisk faces challenges from the continued compounding of GLP-1 drugs and ...